41.35 +0.17 (0.41%)
After hours: 5:34PM EDT
|Bid||41.35 x 200|
|Ask||41.50 x 200|
|Day's Range||40.97 - 43.30|
|52 Week Range||11.30 - 45.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.00|
SAN DIEGO, March 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $41.50 per share. All of the shares are being sold by Arena. In addition, Arena has granted the underwriters a 30-day option to purchase up to 1,275,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.
NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Stock markets rallied Tuesday on gains from the energy and consumer discretionary sector. Wall Street appears to be eagerly awaiting details from the Federal ...
Arena Pharmaceuticals Inc. ticked lower Tuesday after the biotech company announced a secondary offering of shares. Arena shares declined 1.9% after hours, following a surge of 29% to close the regular ...
Arena gapped up by nearly a third Tuesday after its ulcerative colitis drug proved strong in a Phase 2 trial.
SAN DIEGO, March 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that it intends to offer and sell, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters an option to purchase up to an additional 1,125,000 shares of its common stock. All of the shares are being offered by Arena.
Shares of Arena Pharmaceuticals Inc. shot up 34% in premarket trade Tuesday, after the drugmaker reported positive results from a phase 2 trial of its treatment for ulcerative colitis. The rally comes ...
Arena rocketed nearly 30% late Monday after its inflammatory bowel disease drug hit each of its goals in a midstage trial.
Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study. The company is banking on etrasimod, along with its pulmonary arterial hypertension drug, after shifting its focus away from its weight-loss treatment due to underwhelming sales. Arena sold the global commercialization rights to the weight-loss drug, Belviq, to Japanese drugmaker Eisai Co Ltd early last year.
- OASIS trial met primary and all secondary endpoints with statistical significance for patients receiving 2 mg dose of etrasimod for 12 weeks - The 2 mg etrasimod group achieved statistically significant ...
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.
Arena (ARNA) posted narrower-than-expected loss in the fourth quarter of 2017. However, revenues decreased significantly year over year.